Comparative Pharmacology
Head-to-head clinical analysis: CRIXIVAN versus TIVICAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRIXIVAN versus TIVICAY.
CRIXIVAN vs TIVICAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indinavir is a specific, potent, reversible inhibitor of HIV-1 protease. It binds to the active site of the viral protease, preventing the cleavage of viral polyprotein precursors into functional proteins, resulting in the formation of immature, non-infectious virions.
Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration, which is essential for HIV replication.
800 mg orally every 8 hours on an empty stomach (1 hour before or 2 hours after meals) or with a light meal.
50 mg orally once daily, or 50 mg twice daily when coadministered with potent UGT1A1 inducers (e.g., rifampin). For INSTI-naive patients: 50 mg once daily. For INSTI-experienced patients with suspected resistance: 50 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is 1.8 to 2.5 hours in healthy adults; requires dosing every 8 hours.
Terminal elimination half-life approximately 14 hours (range 11-20 hours) in healthy subjects; supports once-daily dosing with a low pharmacokinetic boost.
Primarily fecal (78-82%) with approximately 20% renal excretion of unchanged drug.
Primarily metabolized by UGT1A1 with minor CYP3A4 contribution; 53% of dose excreted in feces (31% as unchanged drug) and 33% in urine (1% unchanged).
Category C
Category C
Antiretroviral
Antiretroviral, integrase inhibitor